The market dynamics of leukapheresis products market are the result of an ongoing struggle to adapt to a fast-moving ecosystem motivated by the rising prevalence of blood diseases, the increased demand of more advanced therapeutic approaches, and the fact that continuous technological innovations do still occur in the field of medical devices. A procedure known as leukapheresis—which implies the separation of white blood cells from blood—has recently been appearing as an important module in the treatment of diverse hematological disorders including leukemia and lymphoma amongst others. The markets are noticing a sharp rise in demand for these technologies because there is a trend of worldwide increase in these diseases.
The market is highly stimulated by the growing incidence of blood-related disorders which include but not limited to anemia, leukemia and hemophilia. Undoubtedly, leukemia is an essential medical issue, hence, it might seem necessary that, more advanced treatment methods for its cure are developed. Recent therapy advancements such as leukapheresis have shown enormous promise in providing an effective way of separating and isolating white blood cells. Also The rising incidence of other blood disorders (particularly lymphoma and myeloma) gives a similar impact on the growing market volume.
One of the driving factors of the leukapheresis products market is the significant cultural need of development of ever more advanced therapies. With healthcare providers and patients in need of more precise and efficacious treatment procedures, apheresis leukocyte removal is rising as the main brig of cellular therapy preparation. The market has undergone a transformation towards personalized medicine. Instead, therapies become individualized, hinged on a person's unique genetic configuration. By removing patients’ T-cells (of the larger white blood cell group), targeted treatments, such as CAR-T therapy and stem-cell transplantation, can be created, thus, leekapheresis enables the use of the so-called precision medicine, which is an emerging trend in medicine.
The next essential element that affects the market is the technological advancement that has been implemented in medical equipment with device updates every other year. This trend underlines an effort by manufacturers in search of new leukapheresis products that exhibit efficient work, fast safe operations and better patient results. Developments using enclosed units for apheresis procedures with lowest possibility to spread infections are also creating additional market potential. Furthermore, it includes automation and complex computer software solutions which will simplify the procedure of manual leukophoresis and make it more accessible and effective for the health care professionals.
Spatially, leukapheresis products market showed various changes in the growth rates on the geographic front. The developed regions, which are followed by well-planned healthcare infrastructure and healthcare expenditure, are at the forefront of growth in this sector North America and Europe dominate on the grounds of the size of the market which they have, and this is in turn due to the combination of factors such as presence of blood disorders, the existence of detailed regulatory environment, and a higher rate of adoption of advanced medical technologies.
Segmentation:
The leukapheresis products market has been segmented into type, application, and end user. On the basis of type, the market has been segmented into leukapheresis devices and leukapheresis disposables. The leukapheresis devices segment has been segmented into apheresis devices, leukapheresis column & cell separators, and leukoreduction filters.
The market, on the basis of application, has been segmented into research applications and therapeutic applications.
On the basis of end user, the market has been segmented into blood component providers and blood centers, hospitals and transfusion centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The leukapheresis products market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European leukapheresis products market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The leukapheresis products market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The leukapheresis products market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players:
Haemonetics, Terumo BCT, Asahi Kasei Medical, STEMCELL Technologies, Macopharma, HemaCare Corporation, Caltag Medsystem, ALLCells, LLC, ZENBIO, Fresenius Kabi, PPA Research Group, StemExpress and others are some of the key players in the leukapheresis products market.
Regional Market Summary: Global Leukapheresis Products Market Share (%), by Region, 2017
Source: America’s Blood Centers, White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the leukapheresis products market owing to the growing number of blood donations, rising incidence and prevalence of leukaemia and growing demand for leukopaks in clinical research. According to the America’s Blood Centers, more than 15 million pints of blood are transfused in the US each year.
Europe is expected to hold the second largest position in the leukapheresis products market. The market growth in this region is attributed to the increasing prevalence of leukemia and well-developed healthcare sector in the region. According to the Cancer Research UK, about 9,900 new cases of leukaemia were reported in UK in 2015.
The leukapheresis products market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the increasing presence of major multinational pharma and biotech companies, and improvement in healthcare access.
The Middle East & Africa has the lowest share of the leukapheresis products market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.
Recent Development
Leukapheresis Products Market, by Type
Leukapheresis Products Market, by Application
Leukapheresis Products Market, by End User
Leukapheresis Products Market, by Region
Leukapheresis Products Market, by Key Players
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)